Compare Cassava Sciences Inc (FLNA) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Texas Instruments Incorporated — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Texas Instruments Incorporated trades at $291.62 (market cap $263.91B). The key difference: Texas Instruments Incorporated is far larger — about 6698.2× Cassava Sciences Inc's market cap, and Texas Instruments Incorporated pays a 2.1% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Texas Instruments Incorporated for 76 Days on average.
| FLNA | TXN | |
|---|---|---|
Market Cap | $39.40M | $263.91B |
Volume | 759,018 | 4,544,426 |
Sector | Health | Technology |
52-Week High | $4.64 | $332.35 |
52-Week Low | $0.68 | $153.33 |
Typical Hold Time | 37 Days | 76 Days |
Enterprise Value | -$43.28M | $270.96B |
Dividend Yield | — | 2.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 7.01% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam for epilepsy research provides a positive catalyst, with patient screening expected by Q1 2027.
Despite operational losses and negative cash flow, analyst consensus is bullish with 8 buy ratings versus 4 hold. The key investment opportunity lies in the clinical progress of simufilam, while risks include sustained cash burn and reliance on successful drug development outcomes in a competitive biotech landscape.
Texas Instruments (TXN) trades at $288.2, down 3.06% today amid a semiconductor sector sell-off. The stock shows strong technical momentum with bullish moving averages and key support at $286. Fundamentally, Q2 2026 EPS beat expectations at $2.14 versus $1.91, driven by data center sales doubling. Revenue growth is accelerating with 2026 projections at $19.5B, while maintaining robust profitability with 31.11% net margins. Recent dividend payments and institutional buying by CalSTRS signal confidence.
Outlook remains positive with 47.7% analyst buy ratings and $325 consensus price target offering 13% upside. Key catalysts include AI-driven data center expansion and industrial recovery. Risks include premium valuation (P/E 43.9) and cyclical semiconductor demand. The earnings recovery trajectory supports continued growth despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
